February 9, 2026- Abbott announced positive early results from the VERITAS Study that show clinically meaningful closure rates of the investigational Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation implant designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue (non-valvular). The results were presented in a late-breaking session at the AF Symposium in Boston on Feb. 6, 2026, and simultaneously published in JACC: Clinical Electrophysiology.
Results from the VERITAS Study show 93.9% of non-valvular AFib patients implanted with the Amulet 360 achieved complete closure of the LAA by 45 days, with no leaks greater than 3 mm. The LAA is a small, structurally complex pouch attached to the upper left chamber (atrium) of the heart, which is the most common place for blood clots to form and can potentially lead to stroke for people with this condition. The Amulet 360 device is a minimally invasive treatment option that can adapt to the unique shape of a patient’s LAA to immediately close it, potentially eliminating the need for blood-thinning medication when clinically appropriate.